Skip to content
Search

Latest Stories

LAW: Planning issues - tips and traps for pharmacists

By Claire Timmings

Planning law affects all property and needs to be carefully considered when a pharmacist is either taking on new premises, making alterations or reconfiguring their business requirements.


The use of a property for a certain activity can fall within a specified “use class”.  Usually, planning permission would be required where there is a change of use between two use classes. There are exceptions which allow you to change from one use to another without planning permission.

Exceptions also apply to certain physical works carried out to a property, though these are limited. If the exception does not apply, you usually need planning permission for those works.

Traditional model 

A traditional High Street pharmacy would usually have the benefit of falling within “use class”A1 as set out in the Schedule to the Town and Country Planning (Use Classes) Order 1987 (the Order).

Sometimes planning permissions can contain conditions which might restrict the use of the property. When buying a new pharmacy, it is important to check whether there is a planning permission and if there are conditions which may restrict or prevent you from using the property in any way, e.g the hours of operation or for deliveries or restricting  the type of occupier.

Where a pharmacy forms part of a health centre development, the pharmacy could fall within the primary use class which covers the health centre (usually Class D1).

For a pharmacy in a health centre to retain a Class D1 use its activities will need to remain ancillary to those of the health centre.

There are various factors that can determine whether or not a pharmacy use is ancillary to the health centre use. Factors which could indicate that the use is not an ancillary use include:

  • the amount of over the counter sales or prescriptions issued by the pharmacy is greater than those issued for the whole of the health centre;
  • the pharmacy has its own signage or access and could operate independently from the health centre.
  • the physical floorspace taken by the pharmacy is greater to the floor space of the health centre.

Where a pharmacy does not necessarily fall within either an A1 or D1 use class (which is usually where the planning permission refers to use as a pharmacy) then it is construed as having a sui generis use.

This is a use which does not fall within any of the use classes specified in the Order and has a use which is specific to that particular property.

Internet pharmacy

Where you use a property for storage and/or distribution purposes this use would usually fall within Class B8 of the Order.

If you introduce a trade counter which is customer facing then you may need to apply for planning permission if the trade/retail use becomes the main use of the property, and not the storage and/or distribution use.

Again, where planning permission is required you need to carefully consider any conditions attached to the permission to make sure they do not prevent or restrict the use that you require.

New development and advertisements

Where any physical works are carried out to a property, these will usually require planning permission unless such works are specifically exempt (i.e. internal alterations) or do not need consent.

Advertisement consent would be required if signage (whether or not it is illuminated) is going to be attached to the exterior of the property or placed within a shop front.

If the property is a listed building you may need to obtain separate listed building consent for any works (including internal works) you intend to carry out.  Failure to obtain listed building consent where it is required is a criminal offence.

Long use and enforcement action

If any works or a change of use have been carried out without planning permission, you will need to check if such changes have become immune from enforcement action because of long use.

For physical works, enforcement action cannot be taken after four years from substantial completion of those works. For other breaches, including breaches of conditions imposed on a planning permission and changes of use, these can be subject to enforcement for ten years.

Enforcement action can also be taken outside those periods if there has been deliberate concealment.

These limitations do not apply to listed buildings, where the local authority has the right to take enforcement action at any time after any breach and potentially pursue criminal proceedings.

The local authority has a variety of enforcement powers and could require you to submit a retrospective planning application to authorise the change. If the breach is serious, they could serve enforcement notices or stop notices which could require you to stop any use/operations at the property or put the property back into its original state (which may not be commercially viable).  Failure to comply with such notices could lead to a fine/imprisonment.

Conclusion

Planning is a complex area and subject to continual change. Legal advice should be obtained to ensure that planning permission for the pharmacy use exists, the conditions are not onerous and restrictive, and if there is a breach, steps are taken to address the risk of enforcement action.

The above is a general overview and we recommend that specific advice is sought for your particular concerns.  If you have any queries please do not hesitate to contact Claire Timmings a legal director and member of the pharmacy transactions team or Dan Murphy an associate in the planning team at Charles Russell Speechlys LLP. Claire can be contacted on claire.timmings@crsblaw.com and Dan on dan.murphy@crsblaw.com

This article also appears in the February issue of Pharmacy Business.

More For You

How to leverage data to drive pharmacy growth

Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy.

Pharmacy challenges: How data can help spot the ‘elephant in the room’

Adopting new technologies is vital for moving pharmacy forward — but are you fully harnessing the data these tools generate?

“Being able to utilise, manage, and interpret the data these technologies provide can help add more value to your business,” said Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy, while speaking at the recent Pharmacy Business Conference.

Keep ReadingShow less
Branded OTC products can boost pharmacy revenue and promote self-care, says PAGB CEO

Michelle Riddalls

How branded OTC products can help struggling community pharmacies - PAGB chief explains

Branded over-the-counter (OTC) products could play a vital role in promoting self-care and supporting the sustainability of community pharmacies, said Michelle Riddalls, CEO of PAGB – the consumer healthcare association – during the recent Pharmacy Business Conference.

Riddalls emphasised that OTC medicines not only enable consumers to better manage their health through self-care but also offer pharmacies an opportunity to increase revenue, particularly during a time of mounting financial pressure.

Keep ReadingShow less
How Peptides Are Transforming Modern Drug Development

Modern Drug Development

How Peptides Are Transforming Modern Drug Development

The pharmaceutical industry is rapidly evolving, embracing new technologies and methodologies. Peptides are emerging as a crucial component in this transformation, offering innovative solutions to drug development. This shift is not only reshaping how drugs are discovered but also enhancing their efficacy and safety.

In recent years, the pharmaceutical landscape has undergone significant changes, driven by advancements in technology and scientific understanding. One of the most promising areas of innovation is the use of peptides in drug development. These short chains of amino acids have proven to be versatile tools, capable of targeting specific cells or molecules with high precision. In this context, certain bpc 157 peptide research peptides have been highlighted for their potential applications in various therapeutic areas, showcasing the promise that peptides hold for modern pharmaceutical studies.

Keep ReadingShow less
Off-patent medicines could save NHS millions—but only if UK remains attractive to suppliers - BGMA

BGMA chief executive Mark Samuels urges government to back off-patent medicines ahead of Life Sciences Plan release.

UK risks losing millions in NHS savings without stronger support for generics - BGMA

The British Generic Manufacturers Association (BGMA) has called on the government to create a more supportive environment for the generics and biosimilars sector, warning that the UK risks missing out on significant NHS savings arising from new off-patent medicines.

According to the BGMA, 31 medicines are due to lose patent protection between January and June 2025, with a further 28 set to follow in the second half of the year.

Keep ReadingShow less
Support for generic medicines manufacturers key to affordable healthcare- Teva UK director

Teva UK sounds alarm on accelerating consolidation of critical generic medicines

Photo credit: gettyimages

Exclusive: Teva UK calls for inclusion of generic manufacturers in policy talks

A healthy and vibrant generics marketplace supports not only patients but also contributes billions of pounds in savings to the drugs bill. However, growing pressures on generic medicine manufacturers could threaten this vital part of the healthcare ecosystem, warns Ryan Ruscoe, senior director of generics and OTC at Teva UK.

Speaking exclusively to Pharmacy Business, Ruscoe stressed the urgent need to address supply chain vulnerabilities, particularly for critical generic medicines.

Keep ReadingShow less